Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

AVTE

Aerovate Therapeutics Inc

Jun 18 • 04:00PM ET

1.41

Dollar change -0.24
Percentage change -14.55	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC VHT VTWG IWV BBC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.03	Insider Own	33.29%	Shs Outstand	27.76M	Perf Week	-93.66%
Market Cap	40.64M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	-2.65%	Shs Float	19.23M	Perf Month	-93.15%
Income	-82.19M	PEG	-	EPS next Q	-0.83	Inst Own	64.74%	Short Float	11.49%	Perf Quarter	-94.52%
Sales	0.00M	P/S	-	EPS this Y	-2.29%	Inst Trans	4.19%	Short Ratio	3.64	Perf Half Y	-92.17%
Book/sh	3.26	P/B	0.43	EPS next Y	40.44%	ROA	-71.09%	Short Interest	2.21M	Perf Year	-91.45%
Cash/sh	3.45	P/C	0.41	EPS next 5Y	-	ROE	-80.58%	52W Range	1.50 - 32.42	Perf YTD	-93.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-114.14%	ROI	-90.08%	52W High	-95.65%	Beta	0.99
Dividend TTM	-	Quick Ratio	6.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-6.00%	ATR (14)	3.10
Dividend Ex-Date	-	Current Ratio	6.65	EPS Y/Y TTM	-30.59%	Oper. Margin	0.00%	RSI (14)	21.85	Volatility	21.91% 12.61%
Employees	51	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	2.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-25.12%	Payout	-	Rel Volume	8.21	Prev Close	1.65
Sales Surprise	-	EPS Surprise	-8.65%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	607.81K	Price	1.41
SMA20	-92.41%	SMA50	-93.21%	SMA200	-92.42%	Trades		Volume	4,989,500	Change	-14.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$35 → $2
Jun-18-24	Downgrade	TD Cowen	Buy → Hold
Jun-18-24	Downgrade	Evercore ISI	Outperform → In-line	$27 → $2
Jun-17-24	Downgrade	Wedbush	Outperform → Neutral	$41 → $3
Jun-17-24	Downgrade	Guggenheim	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Mar-25-24	Resumed	Jefferies	Buy	$21 → $65
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$35
Mar-01-23	Initiated	Guggenheim	Buy	$36
Dec-06-22	Upgrade	BTIG Research	Neutral → Buy	$27
Sep-19-22	Resumed	Wedbush	Outperform	$27
Aug-16-22	Downgrade	BTIG Research	Buy → Neutral
Feb-11-22	Initiated	BTIG Research	Buy	$24
Jul-26-21	Initiated	Wedbush	Outperform	$23
Jul-26-21	Initiated	Jefferies	Buy	$21
Jul-26-21	Initiated	Evercore ISI	Outperform	$30
Jul-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-18-24 09:21AM	Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals (Zacks) -14.55%
Jun-17-24 04:11PM	Aerovate Therapeutics Stock Dropped Over 90%. Heres Why. (Barrons.com) -93.30%
04:04PM	Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke (Investor's Business Daily)
08:32AM	Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
May-21-24 04:15PM	Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) -9.04%
May-13-24 09:54PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire)
Apr-04-24 01:31AM	Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares (GuruFocus.com)
Mar-27-24 09:20AM	Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) +11.11%
Mar-26-24 09:01PM	Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023 (GuruFocus.com)
Mar-25-24 09:53PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-21-24 02:32AM	Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE) (GuruFocus.com)
02:32AM	Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ... (GuruFocus.com)
Mar-06-24 08:00AM	Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair (GlobeNewswire)
Dec-16-23 11:01AM	Insider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ... (GuruFocus.com)
Nov-20-23 04:45PM	Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
Nov-13-23 11:09AM	Aerovate Therapeutics Inc Reports Increased R&D Expenses and Net Loss in Q3 (GuruFocus.com) +8.45%
08:00AM	Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-14-23 08:00AM	Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights (GlobeNewswire)
Jul-22-23 09:29AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-11-23 05:00PM	Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors (GlobeNewswire)
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
Jun-01-23 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-23 01:15PM	Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference (GlobeNewswire)
May-15-23 04:05PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire) -7.45%
Mar-29-23 04:50PM	Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-02-23 08:00AM	Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-12-23 08:07AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-23-23 08:00AM	Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors (GlobeNewswire)
Dec-31-22 08:22AM	Calculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) (Simply Wall St.)
Dec-28-22 10:15PM	12 Best Performing Biotech Stocks in 2022 (Insider Monkey)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga)
Nov-17-22 07:45AM	Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research (GlobeNewswire)
Nov-14-22 07:45AM	Aerovate Therapeutics Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-18-22 08:00AM	Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022 (GlobeNewswire) +5.28%
Sep-05-22 07:17AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 07:50AM	Aerovate Therapeutics Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-02-22 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-22 05:15PM	Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) (GlobeNewswire) -11.25% +5.60%
08:00AM	Aerovate Therapeutics Announces First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 04:45PM	Aerovate Therapeutics Announces Full-Year 2021 Financial Results (GlobeNewswire) +5.72%
Mar-29-22 11:42AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.) +11.35%
Mar-02-22 08:00AM	Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference (GlobeNewswire) +7.32%
Dec-15-21 08:00AM	Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension (GlobeNewswire) +16.31%
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-15-21 08:00AM	Aerovate Therapeutics Announces Third Quarter 2021 Financial Results (GlobeNewswire) -18.94%
Sep-30-21 06:40AM	Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation (Simply Wall St.)
Sep-21-21 05:05AM	48 Biggest Movers From Yesterday (Benzinga)
Sep-17-21 08:00AM	Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index (GlobeNewswire)
Aug-16-21 08:00AM	Aerovate Therapeutics Announces Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-19-21 08:00AM	Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors (GlobeNewswire)
Jul-02-21 04:01PM	Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.37%
Jun-29-21 10:59PM	Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Jun 14 '24	Option Exercise	14.59	10,600	154,654	10,600	Jun 14 06:00 PM
Eldridge George A	SEE REMARKS	Jun 14 '24	Option Exercise	2.14	15,000	32,100	20,022	Jun 14 06:00 PM
Eldridge George A	SEE REMARKS	Jun 14 '24	Sale	25.03	15,000	375,450	5,022	Jun 14 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Jun 14 '24	Sale	25.00	10,600	265,000	0	Jun 14 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jun 13 '24	Option Exercise	2.14	6,000	12,840	11,602	Jun 14 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jun 13 '24	Sale	24.50	6,000	147,000	5,602	Jun 14 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	May 17 '24	Option Exercise	2.14	4,000	8,560	9,602	May 17 07:10 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	May 17 '24	Sale	21.08	4,000	84,332	5,602	May 17 07:10 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 16 '24	Option Exercise	2.14	10,000	21,400	10,000	May 17 07:10 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 16 '24	Sale	21.58	10,000	215,755	0	May 17 07:10 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	May 02 '24	Sale	21.02	1,981	41,631	0	May 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 01 '24	Option Exercise	2.14	10,000	21,400	10,000	May 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	20.34	11,357	230,946	0	May 03 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 17 '24	Option Exercise	2.14	6,853	14,665	8,144	Apr 19 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Apr 17 '24	Option Exercise	1.74	4,000	6,960	7,251	Apr 19 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 17 '24	Sale	22.37	6,853	153,327	1,291	Apr 19 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Apr 17 '24	Sale	22.38	4,000	89,522	3,251	Apr 19 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 16 '24	Option Exercise	2.14	10,000	21,400	10,000	Apr 18 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 16 '24	Sale	24.70	10,000	246,971	0	Apr 18 06:00 PM
Eldridge George A	SEE REMARKS	Apr 10 '24	Option Exercise	2.14	7,500	16,050	9,460	Apr 12 06:00 PM
Eldridge George A	SEE REMARKS	Apr 10 '24	Sale	26.85	7,500	201,392	1,960	Apr 12 06:00 PM
GRAYZEL DAVID S.	Director	Apr 09 '24	Sale	28.15	11,882	334,478	14,502	Apr 11 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Apr 01 '24	Option Exercise	14.59	5,300	77,327	5,300	Apr 03 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 01 '24	Option Exercise	10.61	3,325	35,278	4,616	Apr 03 06:00 PM
Eldridge George A	SEE REMARKS	Apr 01 '24	Option Exercise	2.14	12,495	26,739	14,455	Apr 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Option Exercise	2.14	10,000	21,400	10,000	Apr 03 06:00 PM
Eldridge George A	SEE REMARKS	Apr 01 '24	Sale	31.23	12,495	390,208	1,960	Apr 03 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Sale	30.00	10,000	300,033	0	Apr 03 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Apr 01 '24	Sale	29.19	5,300	154,697	0	Apr 03 06:00 PM
Dake Benjamin T	SEE REMARKS	Apr 01 '24	Sale	31.97	3,325	106,317	1,291	Apr 03 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 28 '24	Option Exercise	2.14	9,000	19,260	12,251	Apr 01 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 28 '24	Sale	29.50	9,000	265,500	3,251	Apr 01 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 27 '24	Option Exercise	10.61	11,068	117,431	12,359	Mar 28 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 27 '24	Sale	27.97	11,068	309,519	1,291	Mar 28 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 25 '24	Option Exercise	10.61	3,432	36,414	4,723	Mar 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 25 '24	Sale	28.01	3,432	96,119	1,291	Mar 27 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Mar 19 '24	Option Exercise	14.59	5,300	77,327	5,300	Mar 20 06:00 PM
Verwijs Marinus	CHIEF TECHNICAL OFFICER	Mar 19 '24	Sale	26.08	5,300	138,243	0	Mar 20 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 18 '24	Option Exercise	5.64	35,057	197,837	36,348	Mar 20 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 18 '24	Option Exercise	1.91	7,000	13,380	10,251	Mar 20 06:00 PM
Dake Benjamin T	SEE REMARKS	Mar 18 '24	Sale	25.90	35,057	908,046	1,291	Mar 20 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 18 '24	Sale	25.87	7,000	181,057	3,251	Mar 20 06:00 PM
Eldridge George A	SEE REMARKS	Mar 13 '24	Option Exercise	2.14	2,016	4,314	3,976	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 13 '24	Sale	25.02	2,016	50,445	1,960	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 12 '24	Option Exercise	2.14	2,051	4,389	4,011	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 12 '24	Sale	25.05	2,051	51,370	1,960	Mar 14 06:00 PM
Eldridge George A	SEE REMARKS	Mar 11 '24	Option Exercise	2.14	3,433	7,347	5,393	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 11 '24	Sale	25.25	3,433	86,667	1,960	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 08 '24	Option Exercise	2.14	114	244	2,074	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 08 '24	Sale	25.00	114	2,850	1,960	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 07 '24	Option Exercise	2.14	22,386	47,906	24,346	Mar 11 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 07 '24	Option Exercise	2.14	8,975	19,206	12,226	Mar 11 06:00 PM
Eldridge George A	SEE REMARKS	Mar 07 '24	Sale	25.00	22,386	559,688	1,960	Mar 11 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Mar 07 '24	Sale	24.50	8,975	219,888	3,251	Mar 11 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 23 '24	Option Exercise	1.74	511	889	3,762	Feb 27 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 23 '24	Sale	19.50	511	9,964	3,251	Feb 27 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 20 '24	Option Exercise	1.74	3,489	6,071	6,740	Feb 22 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Feb 20 '24	Sale	20.23	3,489	70,575	3,251	Feb 22 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Feb 05 '24	Option Exercise	2.02	4,600	9,284	6,209	Feb 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Feb 05 '24	Sale	17.45	4,600	80,249	1,609	Feb 07 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jan 17 '24	Option Exercise	1.74	4,000	6,960	7,251	Jan 19 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Jan 17 '24	Sale	19.50	4,000	78,000	3,251	Jan 19 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Jan 05 '24	Option Exercise	2.02	4,600	9,284	6,209	Jan 08 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Jan 05 '24	Sale	19.16	4,600	88,116	1,609	Jan 08 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 27 '23	Option Exercise	2.14	125	268	3,376	Dec 29 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 27 '23	Sale	24.50	125	3,062	3,251	Dec 29 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 20 '23	Sale	19.50	4,000	78,000	3,251	Dec 22 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 14 '23	Option Exercise	1.74	9,897	17,221	13,148	Dec 15 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 14 '23	Sale	19.50	9,897	192,992	3,251	Dec 15 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 13 '23	Option Exercise	1.74	4,000	6,960	7,251	Dec 22 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 13 '23	Option Exercise	1.74	2,103	3,659	5,354	Dec 15 06:00 PM
Gillies Hunter	CHIEF MEDICAL OFFICER	Dec 13 '23	Sale	19.50	2,103	41,008	3,251	Dec 15 06:00 PM
Dake Benjamin T	SEE REMARKS	Dec 06 '23	Option Exercise	2.05	10,283	21,041	11,574	Dec 07 06:00 PM
Dake Benjamin T	SEE REMARKS	Dec 06 '23	Sale	16.11	10,283	165,628	1,291	Dec 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Dec 05 '23	Option Exercise	2.02	4,600	9,284	6,209	Dec 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Dec 05 '23	Sale	16.30	4,600	74,996	1,609	Dec 07 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 27 '23	Option Exercise	2.06	12,517	25,821	13,808	Nov 29 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 27 '23	Sale	16.24	12,517	203,237	1,291	Nov 29 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 24 '23	Option Exercise	2.14	4,990	10,679	6,281	Nov 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 24 '23	Sale	15.74	4,990	78,548	1,291	Nov 27 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Nov 22 '23	Option Exercise	2.02	13,800	27,852	15,409	Nov 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 22 '23	Option Exercise	2.04	9,382	19,113	10,673	Nov 27 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Nov 22 '23	Sale	15.00	13,800	207,000	1,609	Nov 27 06:00 PM
Dake Benjamin T	SEE REMARKS	Nov 22 '23	Sale	15.17	9,382	142,359	1,291	Nov 27 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Nov 01 '23	Sale	10.42	1,092	11,379	0	Nov 03 05:00 PM
Verwijs Marinus	CHIEF TECHNOLOGY OFFICER	Nov 01 '23	Sale	10.46	970	10,149	0	Nov 03 05:00 PM
Dake Benjamin T	SEE REMARKS	Sep 07 '23	Option Exercise	2.14	30	64	1,321	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Sep 07 '23	Sale	15.01	30	450	1,291	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Sep 06 '23	Option Exercise	1.89	3,931	7,447	5,222	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Sep 06 '23	Sale	15.06	3,931	59,187	1,291	Sep 08 06:00 PM
Dake Benjamin T	SEE REMARKS	Aug 07 '23	Option Exercise	2.05	10,283	21,041	11,574	Aug 09 06:00 PM
Dake Benjamin T	SEE REMARKS	Aug 07 '23	Sale	15.52	10,283	159,580	1,291	Aug 09 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 28 '23	Option Exercise	2.14	5,478	11,723	5,478	Aug 01 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 28 '23	Sale	18.00	5,478	98,604	0	Aug 01 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 17 '23	Option Exercise	2.14	4,522	9,677	4,522	Jul 19 06:00 PM
NOYES TIMOTHY P	CHIEF EXECUTIVE OFFICER	Jul 17 '23	Sale	18.11	4,522	81,896	0	Jul 19 06:00 PM
Dake Benjamin T	SEE REMARKS	Jul 06 '23	Option Exercise	2.05	10,283	21,041	11,574	Jul 07 06:00 PM
Dake Benjamin T	SEE REMARKS	Jul 06 '23	Sale	16.66	10,283	171,284	1,291	Jul 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Jul 05 '23	Option Exercise	2.02	2,250	4,555	3,859	Jul 07 06:00 PM
NIVEN RALPH	CHIEF SCIENTIFIC OFFICER	Jul 05 '23	Sale	17.30	2,250	38,915	1,609	Jul 07 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVTE

Aerovate Therapeutics Inc

Upgrade your FINVIZ experience